Innovative Medicines Initiative (IMI) 4th Call 2011

Based on the recommendations of the IMI Research Agenda, the IMI Governing Board has approved the IMI Annual Implementation Plan 2011, including the Scientific Priorities 2011. These priorities have been incorporated into the IMI 4th Call Topics.

These priorities have been incorporated into the IMI 4th Call Topics. Applicants intending to submit an Expression of Interest (EoI) in response to the IMI 4th Call should read the Guide for Applicants, the Call Topics, the Rules for Participation, the Rules for Submission, Evaluation and Selection of EoIs and FPPs, the IMI IPR rules and the IMI JU model Grant Agreement.

Call Identifier: IMI-JU-2011

Call status: Open for Submission of Expression of Interest from 19 September 2011.

Budget: A maximum financial contribution from the European Community to the IMI JU for the support of research activities of € 105 million, matched by the in-kind contribution by the research based companies that are members of the European Federation of Pharmaceutical Industries and Associations (EFPIA)

Call documents: The key documents required for the preparation of your Expression of Interest (EoI):

  • Call 4 topics text (IMI-GB-DEC-2011-09.1)
  • Guide for Applicants Expressions of Interest (IMI-GB-DEC-201109.4)
  • Rules for Participation (IMI-GB-DEC-2011-09.5)
  • Rules for Submission, Evaluation and Selection of Expressions of Interest and Full Project Proposals (IMI-GB-DEC-2011-09.2)
  • IMI 4th Call Evaluation Form - Stage 1 (IMI-GB-DEC-2011-09.3)
  • IP Policy
  • Model Grant Agreement

Submissions start date (for submitting EoIs): 19 September 2011

Submissions deadline (for submitting EoIs): 18 October 2011

For further information and the key documents, please visit:
http://www.imi.europa.eu/content/stage-1-2

About IMI
The Innovative Medicines Initiative (IMI) is Europe's largest public-private partnership aiming to improve the drug development process by supporting a more efficient discovery and development of better and safer medicines for patients.

With a €2 billion euro budget, IMI supports collaborative research projects and builds networks of industrial and academic experts in Europe that will boost innovation in healthcare. Acting as a neutral third party in creating innovative partnerships, IMI aims to build a more collaborative ecosystem for pharmaceutical research and development (R&D). IMI will provide socio-economic benefits to European citizens, increase Europe's competitiveness globally and establish Europe as the most attractive place for pharmaceutical R&D.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...